Pacira Pharmaceuticals Inc (PCRX)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	41,955	6,983	-4,568	-10,455	15,909	20,881	39,234	38,439	41,980	61,624	174,083	147,733	145,523	126,121	-10,085	-86	-11,016	2,157	7,604	7,438
Total stockholders’ equity	US$ in thousands	870,130	831,551	807,975	768,041	775,010	770,123	756,636	709,576	730,408	718,602	687,168	650,818	619,688	584,690	388,148	374,036	354,944	346,162	341,650	327,519
ROE		4.82%	0.84%	-0.57%	-1.36%	2.05%	2.71%	5.19%	5.42%	5.75%	8.58%	25.33%	22.70%	23.48%	21.57%	-2.60%	-0.02%	-3.10%	0.62%	2.23%	2.27%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $41,955K ÷ $870,130K
= 4.82%

To analyze Pacira BioSciences Inc's return on equity (ROE) based on the data provided, we can observe a fluctuating trend in ROE over the past eight quarters. The ROE has ranged from -1.36% in Q1 2023 to a high of 5.42% in Q1 2022. This variability indicates a lack of consistency in generating profits relative to shareholders' equity.

The downward trend in ROE from Q2 2022 to Q1 2023 suggests deteriorating profitability relative to equity during this period. However, the ROE showed a slight improvement in Q4 2023 compared to the previous quarters.

Overall, Pacira BioSciences Inc's ROE performance fluctuates, indicating potential challenges in efficiently utilizing its equity capital to generate returns for shareholders. Further analysis and investigation into the company's financial management and operational efficiency may be necessary to address the fluctuating ROE trend.